Small-molecule therapies for genetic skin fragility

Molecular Therapy

Volumn 22, Issue 10, 2014, Pages 1724-1725

  Bruckner Tuderman, Leena ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC G 418; ATALUREN; COLLAGEN TYPE 1; COLLAGEN TYPE 6; COLLAGEN TYPE 7; GENTAMICIN; PAROMOMYCIN; AMINOGLYCOSIDE; STOP CODON;

BLISTER; COL7A1 GENE; COLLAGEN SYNTHESIS; CYSTIC FIBROSIS; DRUG SAFETY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FIBROBLAST; GENE; GENE MUTATION; HUMAN; KERATINOCYTE; MOLECULAR THERAPY; MUSCULAR DYSTROPHY; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; NOTE; PROTEIN EXPRESSION; SKIN FRAGILITY; SQUAMOUS CELL CARCINOMA; STOP CODON; DRUG EFFECTS; GENETICS; PROTEIN SYNTHESIS;

AMINOGLYCOSIDES; CODON, NONSENSE; COLLAGEN TYPE VII; HUMANS; PROTEIN BIOSYNTHESIS;

EID: 84926016418     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.169     Document Type: Note

References (14)

1. Fine, J-D, Bruckner-Tuderman, L, Eady, RAJ, Bauer, EA, Bauer, JW, Has, C et al. (2014). The classification of inherited epidermolysis bullosa (EB): report of the Fourth International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 70: 1103-1126.
2. Bruckner-Tuderman, L, McGrath, JA, Robinson, EC and Uitto, J (2013). Progress in epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Invest Dermatol 133: 2121-2126.
3. Cogan, J, Weinstein, J, Wang, X, Hou, Y, Martin, S, South, AP et al. (2014). Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther 22: 1741-1752.
4. Has, C and Bruckner-Tuderman, L (2014). The genetics of skin fragility. Annu Rev Genomics Hum Genet 15: 16.1-16.24.
5. Fritsch, A, Loeckermann, S, Kern, JS, Braun, A, Bösl, MR, Bley, T et al. (2008). A hypomorphic mouse model for dystrophic epidermolysis bullosa reveals disease mechanisms and responds to fibroblast therapy. J Clin Invest 118: 1669-1679.
6. Nyström, A, Velati, D, Mittapalli, VR, Kern, JS, Fritsch, A and Bruckner-Tuderman, L (2013). Collagen VII plays a dual role in wound healing. J Clin Invest 123: 3498-3509.
7. Barton-Davis, ER, Cordier, L, Shoturma, DI, Leland, SE and Sweeney, HL (1999). Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104: 375-381.
8. Bidou, L, Allamand, V, Rousset, J-P and Namy, O (2012). Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med 18: 679-688.
9. Li, M, Andersson-Lendahl, M, Sejersen, T and Arner, A (2014). Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment. FASEB J 28: 1593-1599.
10. Kuschal, C, DiGiovanna, JJ, Khan, SG, Gatti, RA and Kraemer, KH (2013). Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci USA 110: 19483-19488.
11. Myllyharju, J and Kivirikko, KI (2004). Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 20: 33-43.
12. Fang, Y, Bateman, JF, Mercer, JF and Lamandé, SR (2013). Nonsense-mediated mRNA decay of collagen- emerging complexity in RNA surveillance mechanisms. J Cell Sci 126: 2551-2560.
13. Peltz, SW, Morsy, M, Welch, EM and Jacobson, A (2013). Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64: 407-425.
14. Kerem, E, Konstan, MW, De Boeck, K, Accurso, FJ, Sermet-Gaudelus, I, Wilschanski, M et al. (2014). Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2: 539-547.